Researchers have identified that the Ebola virus recruits a host enzyme, PP2A-B56, for replication, demonstrating that inhibiting this pathway could be a target for drug discovery.
Browsing: Emerging Disease > Ebola
Researchers have reported an acceptable safety and immunogenicity profile of an Ebola vaccine in adults and potentially in children in Africa – indicating that the vaccine produces an immune response and is considered safe.
Researchers have examined the cerebrospinal fluid in a small cohort of Ebola survivors, reporting that no viral RNA was present and suggesting the virus may be cell-associated within the CNS.
A live-attenuated Ebola vaccine has demonstrated promising results in a Phase I randomized controlled trial assessing safety and immunogenicity, according to a Canadian study.
Author, Mark Woolhouse, discusses recent efforts to identify pathogens with pandemic potential and his own work on emerging viruses.
Researchers examining post-Ebola syndrome have discovered ocular consequences, including a disease-associated retinal scar.
John-Arne Røttingen discusses his role as founding CEO of the Coalition for Epidemic Preparedness Innovations (CEPI) and his thoughts on the importance of developing new vaccines for emerging threats.
International collaborative research has analyzed Ebola virus genomes from the 2013–2016 outbreak, uncovering the role of factors such as language and distance between cities.